Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease

FDA clearance of the IND (along with a previously cleared CTA) establishes a global Phase 1/2 clinical program for PM577a. PM577a is designed to target the H1069Q ATP7B mutation, the most prevalent WD-causing allele in North America and Europe. The regulatory greenlight is a meaningful positive step for the program’s development timeline.

Analysis

FDA clearance of the IND (along with a previously cleared CTA) establishes a global Phase 1/2 clinical program for PM577a. PM577a is designed to target the H1069Q ATP7B mutation, the most prevalent WD-causing allele in North America and Europe. The regulatory greenlight is a meaningful positive step for the program’s development timeline.